Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany.

Jakob Cramer; Trang Mac; B Hogan; Sabine Stauga; Sabine Eberhardt; O Wichmann; T Mertens; Gerd-Dieter Burchard

Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany.

Standard

Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany. / Cramer, Jakob; Mac, Trang; Hogan, B; Stauga, Sabine; Eberhardt, Sabine; Wichmann, O; Mertens, T; Burchard, Gerd-Dieter.

in: EUROSURVEILLANCE, Jahrgang 17, Nr. 2, 2, 2012.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Cramer, J, Mac, T, Hogan, B, Stauga, S, Eberhardt, S, Wichmann, O, Mertens, T & Burchard, G-D 2012, 'Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany.', EUROSURVEILLANCE, Jg. 17, Nr. 2, 2. <http://www.ncbi.nlm.nih.gov/pubmed/22264864?dopt=Citation>

APA

Cramer, J., Mac, T., Hogan, B., Stauga, S., Eberhardt, S., Wichmann, O., Mertens, T., & Burchard, G-D. (2012). Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany. EUROSURVEILLANCE, 17(2), [2]. http://www.ncbi.nlm.nih.gov/pubmed/22264864?dopt=Citation

Vancouver

Cramer J, Mac T, Hogan B, Stauga S, Eberhardt S, Wichmann O et al. Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany. EUROSURVEILLANCE. 2012;17(2). 2.

Bibtex

@article{17d2b83250634a7e88913981f1b7b421,

title = "Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany.",

abstract = "The 2009 influenza pandemic has introduced the new re-assorted influenza A(H1N1)pdm09 virus which recirculated during the 2010/11 influenza season. Before that season, it was possible to acquire protective immunity either by pandemic or seasonal influenza vaccination against influenza A(H1N1)pdm09 or by natural infection. To obtain data on vaccination coverage and antibody levels in a reference population and to calculate whether or not the herd immunity threshold (HIT, calculated as 33% given an R0 of 1.5) was reached at the beginning of the 2010/11 season we performed a seroprevalence study in November 2010 in Hamburg, Germany. Antibody titres were assessed applying a haemagglutination inhibition test. Vaccination coverage was very low: 14% for pandemic and 11% for seasonal 2010/11 vaccinations. Even in those with underlying risk factors, vaccination coverage was not much higher: 17% for both vaccines. Serological analysis revealed antibody titres of ?1:10 in 135 of 352 (38%) and of ?1:40 in 61 of 352 study participants (17%). Specific antibodies were measurable in 26% of those without history of vaccination or natural infection, indicating a high proportion of subclinical and mild influenza disease. Nevertheless, the HIT was not reached, leaving the majority of the population susceptible to influenza A(H1N1)pdm09 and its potential complications.",

keywords = "Adult, Humans, Male, Aged, Middle Aged, Risk Factors, Adolescent, Questionnaires, Young Adult, Cross-Sectional Studies, Prevalence, Germany/epidemiology, Antibodies, Viral/*blood, Hemagglutination Inhibition Tests, Influenza A Virus, H1N1 Subtype/*immunology, Seasons, Seroepidemiologic Studies, Influenza, Human/*epidemiology/prevention & control, Influenza Vaccines/*administration & dosage/*immunology, Pandemics, Vaccination, Adult, Humans, Male, Aged, Middle Aged, Risk Factors, Adolescent, Questionnaires, Young Adult, Cross-Sectional Studies, Prevalence, Germany/epidemiology, Antibodies, Viral/*blood, Hemagglutination Inhibition Tests, Influenza A Virus, H1N1 Subtype/*immunology, Seasons, Seroepidemiologic Studies, Influenza, Human/*epidemiology/prevention & control, Influenza Vaccines/*administration & dosage/*immunology, Pandemics, Vaccination",

author = "Jakob Cramer and Trang Mac and B Hogan and Sabine Stauga and Sabine Eberhardt and O Wichmann and T Mertens and Gerd-Dieter Burchard",

year = "2012",

language = "English",

volume = "17",

journal = "EUROSURVEILLANCE",

issn = "1025-496X",

publisher = "Centre Europeen pour la Surveillance Epidemiologique du SIDA",

number = "2",

}

RIS

TY - JOUR

T1 - Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany.

AU - Cramer, Jakob

AU - Mac, Trang

AU - Hogan, B

AU - Stauga, Sabine

AU - Eberhardt, Sabine

AU - Wichmann, O

AU - Mertens, T

AU - Burchard, Gerd-Dieter

PY - 2012

Y1 - 2012

N2 - The 2009 influenza pandemic has introduced the new re-assorted influenza A(H1N1)pdm09 virus which recirculated during the 2010/11 influenza season. Before that season, it was possible to acquire protective immunity either by pandemic or seasonal influenza vaccination against influenza A(H1N1)pdm09 or by natural infection. To obtain data on vaccination coverage and antibody levels in a reference population and to calculate whether or not the herd immunity threshold (HIT, calculated as 33% given an R0 of 1.5) was reached at the beginning of the 2010/11 season we performed a seroprevalence study in November 2010 in Hamburg, Germany. Antibody titres were assessed applying a haemagglutination inhibition test. Vaccination coverage was very low: 14% for pandemic and 11% for seasonal 2010/11 vaccinations. Even in those with underlying risk factors, vaccination coverage was not much higher: 17% for both vaccines. Serological analysis revealed antibody titres of ?1:10 in 135 of 352 (38%) and of ?1:40 in 61 of 352 study participants (17%). Specific antibodies were measurable in 26% of those without history of vaccination or natural infection, indicating a high proportion of subclinical and mild influenza disease. Nevertheless, the HIT was not reached, leaving the majority of the population susceptible to influenza A(H1N1)pdm09 and its potential complications.

AB - The 2009 influenza pandemic has introduced the new re-assorted influenza A(H1N1)pdm09 virus which recirculated during the 2010/11 influenza season. Before that season, it was possible to acquire protective immunity either by pandemic or seasonal influenza vaccination against influenza A(H1N1)pdm09 or by natural infection. To obtain data on vaccination coverage and antibody levels in a reference population and to calculate whether or not the herd immunity threshold (HIT, calculated as 33% given an R0 of 1.5) was reached at the beginning of the 2010/11 season we performed a seroprevalence study in November 2010 in Hamburg, Germany. Antibody titres were assessed applying a haemagglutination inhibition test. Vaccination coverage was very low: 14% for pandemic and 11% for seasonal 2010/11 vaccinations. Even in those with underlying risk factors, vaccination coverage was not much higher: 17% for both vaccines. Serological analysis revealed antibody titres of ?1:10 in 135 of 352 (38%) and of ?1:40 in 61 of 352 study participants (17%). Specific antibodies were measurable in 26% of those without history of vaccination or natural infection, indicating a high proportion of subclinical and mild influenza disease. Nevertheless, the HIT was not reached, leaving the majority of the population susceptible to influenza A(H1N1)pdm09 and its potential complications.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Middle Aged

KW - Risk Factors

KW - Adolescent

KW - Questionnaires

KW - Young Adult

KW - Cross-Sectional Studies

KW - Prevalence

KW - Germany/epidemiology

KW - Antibodies, Viral/blood

KW - Hemagglutination Inhibition Tests

KW - Influenza A Virus, H1N1 Subtype/immunology

KW - Seasons

KW - Seroepidemiologic Studies

KW - Influenza, Human/epidemiology/prevention & control

KW - Influenza Vaccines/administration & dosage/immunology

KW - Pandemics

KW - Vaccination